Infex Therapeutics

Private

Alderley EdgeHealthcare & Life Scienceshttps://www.infextx.com/

Last Round

VC Round

May 12, 2026

Total Funding Raised

$2.35M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Infex Therapeutics is a biotechnology company that acquires, develops, and licenses innovative drugs to treat pandemic and critical priority infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

antimicrobial resistanceAMRanti-infective therapiesclinical-stage biotechdrug-resistant infectionssuperbugsout-licensing modelanti-virulence therapyasset-centric biotechmonoclonal antibodypharma partnershipsresistance bypassGram-negative bacteriaMBL inhibitorpathoblockersdrug discoverymilestone payments

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Infex Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Infex Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Infex Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
VC Round	May 12, 2026
Grant	Feb 17, 2025
Grant	Aug 8, 2022
VC Round	Mar 22, 2019

View all Funding Rounds

Key People

Founding team and executive leadership

Dawn Watson

CFO

Executive Team

Infex Therapeutics Investors

Notable investors and investment history

Infex Therapeutics investors
Investor	Rounds
PACE (Pathways to Antimicrobial Clinical Efficacy)	Grant
Innovate UK	Grant
LifeArc	VC Round
Catapult Ventures	VC Round
Catapult Ventures	VC Round

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 12, 2026
$5.8M round led by Jon Moulton
Mar 2, 2026
Monthly visitors grew 47% MoM, from 961 to 1.4K.

View all signals

Infex Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Infex Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Infex Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAlderley Edge

Employee Range24

Year Founded2016

Last FundingMay 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.